Alongside promising first HAE data, Intellia posts readout in Regeneron-partnered ATTR program

In August, Alnylam touted a Phase III success for transthyretin amyloidosis, or ATTR for short, with cardiomyopathy — a disease that causes protein buildup in the heart, so it can’t pump at full capacity. However, Intellia and Regeneron are here to compete, with a therapy that only needs to be dosed…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.